ArticleClinical & translational immunology2021
The IL-27/IL-27R axis is altered in CD4
Article in Clinical & translational immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 16 citations in OpenAlex.
- Discordant Interleukin-27 (IL-27) Subunit Transcription in Human Sepsis Exposes a Molecular-Attribution Gap.Biomedicines · 2026Article
- Reframing IL-27: a central regulator of CD8Trends in immunology · 2026Review
- Sex Bias in IL-10 Production by Type I Regulatory T Cells Regulated by PI3K/mTOR Signaling.Neurology(R) neuroimmunology & neuroinflammation · 2026Article
- Recent Insights Into Targeting Interleukin-27 in Coronary Artery Disease.Journal of cardiovascular translational research · 2025Review
- Dysregulated lipid metabolism networks modulate T-cell function in people with relapsing-remitting multiple sclerosis.Clinical and experimental immunology · 2024Article
- IL-27 promotes pathogenic T cells in a mouse model of Sjögren's disease.Clinical immunology (Orlando, Fla.) · 2024Article
- An updated advancement of bifunctional IL-27 in inflammatory autoimmune diseases.Frontiers in immunology · 2024Review
- Interleukin 27, like interferons, activates JAK-STAT signaling and promotes pro-inflammatory and antiviral states that interfere with dengue and chikungunya viruses replication in human macrophages.Frontiers in immunology · 2024Article
- IL-27 increases energy storage in white adipocytes by enhancing glucose uptake and fatty acid esterification.Adipocyte · 2023Article
- IL-27 shapes the immune properties of human astrocytes and their impact on encountered human T lymphocytes.Journal of neuroinflammation · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesPro- and anti-inflammatory properties have been attributed to interleukin-27 (IL-27). Nevertheless, the impact of this cytokine on chronic inflammatory diseases such as multiple sclerosis (MS) remains ill-defined. We investigated the biology of IL-27 and its specific receptor IL-27Rα in MS patients.
methodsLevels of IL-27 and its natural antagonist (IL-27-Rα) were measured by ELISA in biological fluids. CD4
resultsWe observed elevated levels of IL-27 in the serum and cerebrospinal fluid of MS patients compared with controls. Moreover, we show that specific IL-27-mediated effects on T lymphocytes are reduced in MS patients including the induction of PD-L1. IL-27-triggered STAT3 signalling pathway is enhanced in CD4
conclusionOur work identifies several mechanisms that are altered in the IL-27/IL-27R axis in MS patients, especially in T lymphocytes. Our results underline the importance of characterising the biology of cytokines in human patients prior to design new therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.